1E, F), making it difficult to extricate the other phenotypes potentially caused by the loss of GSH
This medication mimics the activity of the natural hormone glucagon-like peptide-1, which acts on the brain and gut to regulate hunger and satiety
4 Medicare coverage for GLP-1 drugs for obesity will begin in spring 2026, starting with a pilot program that could become mandatory in 2027
Needle size, injection site, and dosage will differ for every individual
Prevention isn't just possible, it's essential
Research has shown that, in addition to improving glycaemic control and weight loss, GLP-1RAs can impact other risk factors for cardiovascular (CV) complications, including lowering systolic blood pressure and modifying plasma lipids and markers of inflammation [18]